| Title |
European Society for Medical Oncology (ESMO) Asia Congress 2022 |
| Description |
Conclusions: NIVO + chemo did not show statistically significant improvement in PFS in pts with EGFR-mut mNSCLC after progression on EGFR TKIs; however, a trend of benefit was seen in pts with sensitizing EGFR mutations and in those with 1 prior line of EGFR TKI tx. No new safety signals were identified. |
| Organism |
Homo sapiens |
| Data Type |
Other Type of Metabolome Data |
| Data Accessibility |
Open-access |
| BioProject |
PRJCA012509 |
| Release Date |
2022-10-18 |
| Submitter |
Qi Zhang (qi.zhang@ppd.com) |
| Organization |
Guangdong Provincial People's Hospital |
| Submission Date |
2022-10-14 |